Core Viewpoint - Anxu Bio (688075) has disclosed its 2025 performance forecast, expecting a significant decline in net profit and a delay in its fundraising project until 2027 [1] Financial Performance - The company anticipates a net profit attributable to shareholders of 71 million to 85 million yuan, representing a year-on-year decrease of 55.80% to 63.08% [2] - The expected non-recurring net profit is projected to be between 13 million and 15.6 million yuan, reflecting a year-on-year decline of 58.84% to 65.70% [2] - The performance decline is primarily attributed to increased tariffs in the U.S. leading to reduced orders, foreign exchange losses due to currency fluctuations, decreased interest income, and asset depreciation [2] Project Progress - The company announced on January 30, 2026, that the completion date for its "in vitro diagnostic reagents and diagnostic instruments R&D and production project" has been postponed from January 2026 to January 2027 [3] - The delay is attributed to the impact of global respiratory infectious diseases on renovation progress and delays in equipment investment [3] Company Status - Shareholder Ma Huaxiang reduced his stake in the company by selling 804,500 shares between January 6 and January 21, 2026, decreasing his holding from 11.62% to 10.99%, which has reached the 1% threshold for equity change [4] Business and Technical Development - The company is actively transitioning from a single product focus to a comprehensive health management approach, including the expansion of pet testing products and chronic disease management apps [5] - The company is deepening its overseas market presence, with multiple international certifications expected in 2025, although related investments may lead to increased short-term expenses [5]

Group 1: 2025 Annual Performance Forecast - The company expects a net profit attributable to shareholders of 71 million to 85 million yuan for 2025, a decrease of 10,729.53 million to 12,129.53 million yuan compared to the previous year, representing a year-on-year decline of 55.80% to 63.08% [1] - The forecasted net profit attributable to shareholders after deducting non-recurring gains and losses is estimated to be between 13 million and 15.6 million yuan, a decrease of 2,229.79 million to 2,489.79 million yuan compared to the previous year, reflecting a year-on-year decline of 58.84% to 65.70% [1] Group 2: Previous Year Performance - In the previous year, the total profit was 21,064.01 million yuan, with a net profit attributable to shareholders of 19,229.53 million yuan and a net profit after deducting non-recurring gains and losses of 3,789.79 million yuan [2] Group 3: Reasons for Performance Changes - The company's main business remains stable, but increased strategic investments in new technology platforms and expansion in domestic and international markets have led to higher costs. Additionally, U.S. tariffs have reduced orders in certain regions, contributing to increased operating costs and a decline in profits due to exchange rate fluctuations, reduced interest income, and asset depreciation [4] Group 4: Fundraising Project Delay - The company has decided to postpone the completion date of the "in vitro diagnostic reagents and diagnostic instruments R&D and production project" from January 2026 to January 2027, without changing the investment content or total amount [9][10] - The delay is due to construction progress being slowed by global respiratory infectious diseases, affecting internal and external renovations, and the need for further payments related to the project [11][12] - The postponement is a prudent decision based on the actual situation of the project and will not adversely affect the company's normal operations or long-term development plans [12]

Core Viewpoint - Hangzhou Anxu Biotechnology Co., Ltd. is expected to experience a significant decline in net profit for the year 2025, primarily due to increased tariffs, rising operating costs, and other financial factors [1] Financial Performance - The company forecasts a net profit attributable to shareholders of between 71 million yuan and 85 million yuan for 2025, representing a year-on-year decrease of 55.80% to 63.08% [1] - The net profit after deducting non-recurring gains and losses is projected to be between 13 million yuan and 15.6 million yuan, reflecting a year-on-year decline of 58.84% to 65.70% [1] Factors Influencing Performance - The decline in performance is attributed to several factors, including: - Increased tariffs from the United States leading to reduced orders - Rising operating costs - Exchange rate fluctuations and foreign exchange losses - Decreased interest income - Increased asset depreciation and amortization [1] Strategic Investments - The company is increasing its investment in new technology platforms and expanding its overseas market presence, which has resulted in higher expenses [1]

Core Viewpoint - Anxue Bio (688075.SH) forecasts a significant decline in net profit for the year 2025, projecting a range of 71 million to 85 million yuan, which represents a decrease of approximately 55.80% to 63.08% compared to the previous year [1] Group 1: Financial Performance - The expected net profit for 2025 is between 71 million and 85 million yuan, down from the previous year's figures by 107.2953 million to 121.2953 million yuan [1] - The year-on-year decline in net profit is projected to be between 55.80% and 63.08% [1] Group 2: Business Operations - The company maintains steady development in its core business operations [1] - To strengthen its long-term competitive advantage in the industry, the company continues to invest strategically in new technology platforms while ensuring the advancement of its existing platforms [1] - Increased expenses are attributed to the expansion of domestic and international markets, as well as the establishment of overseas subsidiaries [1]

Core Viewpoint - Anxu Bio (688075.SH) forecasts a significant decline in net profit for the year 2025, projecting a net profit attributable to shareholders of between 71 million to 85 million yuan, representing a decrease of 107.30 million to 121.30 million yuan compared to the previous year, which translates to a year-on-year decline of 55.80% to 63.08% [1] Group 1 - The company's main business remains stable, indicating ongoing operational resilience despite the projected profit decline [1] - To strengthen its long-term competitive advantage in the industry, the company is maintaining the advancement of its existing technology platforms while strategically investing in new technology platforms [1] - Increased expenses are attributed to the expansion of domestic and international markets, as well as the establishment of overseas subsidiaries [1]

Group 1 - The company, Anxu Bio, announced an expected net profit attributable to shareholders of the parent company for the year 2025, ranging from 71 million to 85 million yuan [2]

Core Viewpoint - Anxu Biotech announced a delay in the timeline for its fundraising investment project related to the research and production of in vitro diagnostic reagents and instruments, pushing the expected operational date from January 2026 to January 2027 [2]. Group 1 - Anxu Biotech held its third board meeting and the third audit committee meeting on January 30, 2026 [2]. - The company approved a proposal to postpone the expected operational date for its fundraising investment project [2].

Group 1 - The company Anxu Biotech (688075) expects a significant decline in net profit for 2025, projecting a range of 71 million to 85 million yuan, representing a year-on-year decrease of 55.8% to 63.08% [4] - The expected non-recurring net profit for the same period is estimated to be between 13 million and 15.6 million yuan, indicating a year-on-year decline of 58.84% to 65.7% [4] - As of January 30, the company's price-to-earnings ratio (TTM) is approximately 60.16 to 72.03 times, with a price-to-book ratio (LF) of about 0.99 times and a price-to-sales ratio (TTM) of around 11.05 times [4] Group 2 - The company's main business involves POCT (Point of Care Testing) reagents and instruments [7] - The decline in profit is attributed to several factors, including increased costs due to U.S. tariffs, rising operational expenses from expanding technology platforms, and losses from currency fluctuations [7] - The company is maintaining its competitive advantage by investing in new technology platforms while also expanding its market presence both domestically and internationally [7]

Core Viewpoint - Anxu Bio (688075.SH) expects a significant decline in net profit for the year 2025, with projections indicating a decrease of 55.80% to 63.08% compared to the previous year [1] Financial Performance - The company anticipates a net profit attributable to shareholders of 71 million to 85 million yuan for 2025 [1] - The expected net profit after deducting non-recurring gains and losses is projected to be between 13 million and 15.6 million yuan, reflecting a year-on-year decrease of 58.84% to 65.70% [1] Business Development - The company's main business remains stable, and it continues to invest strategically in new technology platforms while maintaining the advancement of existing ones [1] - Efforts to expand in domestic and international markets, as well as obtaining registration certificates, have led to increased expenses [1] External Factors - The increase in tariffs imposed by the U.S. government has resulted in a reduction of orders in certain regional markets, contributing to higher operating costs for the company [1] - Additional factors affecting profit include exchange rate fluctuations leading to foreign exchange losses, reduced interest income, and depreciation and amortization of assets [1]

国联民生证券承销保荐有限公司 关于杭州安旭生物科技股份有限公司 部分募集资金投资项目延期的核查意见 国联民生证券承销保荐有限公司（以下简称"国联民生保荐"、"保荐机构"） 作为杭州安旭生物科技股份有限公司（以下简称"安旭生物"、"公司"）首次公 开发行股票并在科创板上市的持续督导机构，根据《证券发行上市保荐业务管理办 法》、《上海证券交易所科创板股票上市规则》以及《上海证券交易所上市公司自律 监管指引第11号——持续督导》等法律法规和规范性文件的要求，对杭州安旭生物科 技股份有限公司部分募集资金投资项目延期进行了核查，核查情况及核查意见如下： 三、募集资金投资项目延期的具体情况及原因 （一）本次募集资金投资项目延期的基本情况 公司结合目前募集资金投资项目的实际建设情况和投资进度，在募集资金投资用 途及投资规模不发生变更的情况下，将募集资金投资项目"体外诊断试剂以及诊断仪 器研发生产项目"原计划达到预定可使用状态日期由2026年1月调整至2027年1月。 一、募集资金基本情况 根据中国证券监督管理委员会于2021年9月28日出具的《关于同意杭州安旭生物 科技股份有限公司首次公开发行股票注册的批复》（证监许可〔2 ...